Insider · CIK 0001830328
Richard Adcock
Files at IBRX (ImmunityBio, Inc.). First filing -, latest -.
In brief
Richard Adcock files SEC Form 4 as CEO, president and director at IBRX (ImmunityBio, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Richard Adcock has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 17 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 22, 2026 | IBRX ImmunityBio, Inc. | MOption exercise Common Stock | +152,439 | $0.00 | $0 | 637,904 | Feb 24, 2026 |
| Feb 22, 2026 | IBRX ImmunityBio, Inc. | FTax withholding Common Stock | -77,560 | $8.70 | $675k | 560,344 | Feb 24, 2026 |
| Feb 22, 2026 | IBRX ImmunityBio, Inc. | MOption exercise Restricted Stock Unitsderivative | -152,439 | $0.00 | $0 | 152,439 | Feb 24, 2026 |
| Feb 10, 2026 | IBRX ImmunityBio, Inc. | MOption exercise Common Stock | +274,122 | $0.00 | $0 | 625,513 | Feb 12, 2026 |
| Feb 10, 2026 | IBRX ImmunityBio, Inc. | FTax withholding Common Stock | -140,048 | $6.93 | $971k | 485,465 | Feb 12, 2026 |
| Feb 10, 2026 | IBRX ImmunityBio, Inc. | MOption exercise Restricted Stock Unitsderivative | -274,122 | $0.00 | $0 | 548,246 | Feb 12, 2026 |
| Dec 31, 2025 | IBRX ImmunityBio, Inc. | MOption exercise Common Stock | +34,483 | $0.00 | $0 | 368,901 | Jan 5, 2026 |
| Dec 31, 2025 | IBRX ImmunityBio, Inc. | FTax withholding Common Stock | -17,510 | $1.98 | $35k | 351,391 | Jan 5, 2026 |
| Dec 31, 2025 | IBRX ImmunityBio, Inc. | MOption exercise Restricted Stock Unitsderivative | -34,483 | $0.00 | $0 | 51,731 | Jan 5, 2026 |
| Feb 22, 2025 | IBRX ImmunityBio, Inc. | MOption exercise Common Stock | +152,439 | $0.00 | $0 | 412,585 | Feb 25, 2025 |
| Feb 22, 2025 | IBRX ImmunityBio, Inc. | FTax withholding Common Stock | -78,167 | $3.42 | $267k | 334,418 | Feb 25, 2025 |
| Feb 22, 2025 | IBRX ImmunityBio, Inc. | MOption exercise Restricted Stock Unitsderivative | -152,439 | $0.00 | $0 | 304,878 | Feb 25, 2025 |
| Feb 10, 2025 | IBRX ImmunityBio, Inc. | AGrant or award Restricted Stock Unitsderivative | +822,368 | $0.00 | $0 | 822,368 | Feb 12, 2025 |
| Feb 10, 2025 | IBRX ImmunityBio, Inc. | AGrant or award Stock Option (right to buy)derivative | +2,812,500 | $0.00 | $0 | 2,812,500 | Feb 12, 2025 |
| Dec 31, 2024 | IBRX ImmunityBio, Inc. | MOption exercise Common Stock | +34,483 | $0.00 | $0 | 277,621 | Jan 3, 2025 |
| Dec 31, 2024 | IBRX ImmunityBio, Inc. | FTax withholding Common Stock | -17,475 | $2.56 | $45k | 260,146 | Jan 3, 2025 |
| Dec 31, 2024 | IBRX ImmunityBio, Inc. | MOption exercise Restricted Stock Unitsderivative | -34,483 | $0.00 | $0 | 86,214 | Jan 3, 2025 |
Questions about Richard Adcock
Answered from the filings on this page, as of the latest one.
Is Richard Adcock buying or selling?
Richard Adcock has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Richard Adcock's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Richard Adcock has 0.
Where does Richard Adcock file Form 4?
Richard Adcock has filed Form 4 at IBRX (ImmunityBio, Inc.) as CEO & President. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.